Allogene Therapeutics, Inc. (NASDAQ:ALLO) has earned a consensus recommendation of “Buy” from the twelve analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $45.13.
ALLO has been the subject of a number of recent research reports. Jefferies Financial Group restated a “buy” rating and set a $53.00 price objective on shares of Allogene Therapeutics in a research note on Thursday, July 1st. Oppenheimer reissued a “buy” rating on shares of Allogene Therapeutics in a research note on Monday, April 12th. B. Riley assumed coverage on Allogene Therapeutics in a research note on Friday, May 14th. They issued a “buy” rating and a $52.00 price target for the company. Truist Securities raised Allogene Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from $34.00 to $41.00 in a research note on Thursday, May 20th. Finally, Truist raised Allogene Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from $34.00 to $41.00 in a research note on Thursday, May 20th.
In other news, General Counsel Veer Bhavnagri sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 18th. The stock was sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the sale, the general counsel now directly owns 426,353 shares of the company’s stock, valued at approximately $12,790,590. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Owen N. Witte sold 9,969 shares of the firm’s stock in a transaction dated Wednesday, June 9th. The stock was sold at an average price of $25.05, for a total value of $249,723.45. Following the sale, the director now directly owns 236,182 shares of the company’s stock, valued at $5,916,359.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 19,969 shares of company stock valued at $507,473. Company insiders own 26.30% of the company’s stock.
Shares of ALLO stock traded down $0.26 on Friday, hitting $22.39. 5,546 shares of the stock traded hands, compared to its average volume of 1,181,496. Allogene Therapeutics has a 1-year low of $21.32 and a 1-year high of $44.92. The stock’s fifty day moving average is $25.00.
Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings data on Tuesday, May 4th. The company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.21. The company had revenue of $38.35 million for the quarter, compared to the consensus estimate of $24.50 million. On average, equities research analysts forecast that Allogene Therapeutics will post -1.99 earnings per share for the current fiscal year.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
Featured Article: Dual Listing
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.